Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
PHASE1CompletedINTERVENTIONAL
Enrollment
120
Participants
Timeline
Start Date
October 31, 1998
Study Completion Date
September 30, 2000
Conditions
FeverMycosesNeutropenia
Interventions
DRUG
FK463
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001790 - Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia | Biotech Hunter | Biotech Hunter